Key points from article :
US FDA granted fast track designation for Prothena to develop next-generation treatment for Alzheimer’s disease, PRX012.
Investigational amyloid beta (Aβ) targeting therapy is being investigated in a Phase 1 study for Alzheimer’s.
“With substantially higher binding strength for simple subcutaneous administration, PRX012 is positioned to potentially lead a paradigm shift in Alzheimer’s treatment,” - Gene Kinney, Prothena CEO.
The drug enables subcutaneous dosing on a patient-friendly, convenient administration schedule.
PRX012 showed 11 times higher binding affinity than approved treatment (aducanumab), said Hideki Garren, chief medical officer.
“PRX012 can clear both pyroglutamate-modified and -unmodified Aβ plaque.”
Also developing PRX005 (anti-tau antibody) in conjunction with Bristol-Myers Squibb, specifically targeting microtubule binding region.
Developing a single vaccine that concurrently targets amyloid beta and tau to prevent and eradicate Alzheimer’s.
